Differentially expressed circulating miRNAs in postmenopausal osteoporosis: a meta-analysis

Pala, Elif; Denkçeken, Tuba

doi:10.1042/bsr20190667

Cited by 26 publications

(21 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior to this, studies have suggested aberrant expressions of miRs as an inevitable feature of various disorders which include osteoporosis, also miRs are important diagnostic biomarkers in osteoporosis. 15 Looking into the earlier studies involved the profiling of miRNAs in osteoporosis, we evidenced miR-125b as a dysregulated miRNA in the 3 databases which we screened and the expression levels of miR-125b in postmenopausal subjects confirmed these results.We first assessed the function of miR-125b in MC3T3-E1 cells, the outcomes indicated that miR-125b inhibited the cell viability and promoted the release of lactate dehydrogenase. The in vivo experiments in rats suggested that miR-125b decreased the bone mineral density and other biomechanical features of femur bones in rats.…”

Section: Discussionsupporting

confidence: 62%

Overexpression of miR125b Promotes Osteoporosis Through miR-125b-TRAF6 Pathway in Postmenopausal Ovariectomized Rats

Wang¹,

Zhang²,

Yan³

et al. 2021

DMSO

View full text Add to dashboard Cite

Background Postmenopausal osteoporosis is one of the most common types of osteoporosis that women suffer from. Studies involving molecular mechanisms for designing better therapeutic strategies for postmenopausal osteoporosis are still rare. The present study investigates the role of miR-125b in postmenopausal osteoporosis. Methods Microarray analysis was done to screen the gene database. Tissue samples of postmenopausal women were collected to study the miRNA profiles. MC3T3-E1 cells were used and were submitted for transfection. CCK-8 assay was done to check the viability of cells, whereas toxicity was done by lactate dehydrogenase assay kit. TargetScan was done to target genes of miR-125b followed by confirmation by Luciferase reporter assay. For animal studies a rat model of ovariectomized rats was created. Bone mineral density and biomechanics were measured by densitometer. The mRNA levels were assessed by qRT-PCR and proteins by Western blot assay. Results miR-125b was over-expressed in human osteoporosis samples. In vitro studies suggested that miR-125b suppressed the cell viability and promoted release of LDH, it also enhanced the RANKL/OPG ratio and suppressed levels of BMP2 and Runx2. Bioinformatics identified TRAF6 as a potential target of miR-125b, further confirmed by luciferase assay, also miR-125b negatively regulated the levels of TRAF6 gene in osteoporosis bones involving the JAK2/STAT3 cascade. In the rat model, miR-125b decreased the bone mineral density and biomechanical parameters in bones by altering the TRAF6 gene involving the JAK2/STAT3 pathway. Conclusion The outcomes suggested that miR-125b was responsible for the development of postmenopausal osteoporosis and promoted its progression by the TRAF6 gene via the JAK2/STAT3 pathway.

show abstract

Section: Discussionsupporting

confidence: 62%

Overexpression of miR125b Promotes Osteoporosis Through miR-125b-TRAF6 Pathway in Postmenopausal Ovariectomized Rats

Wang¹,

Zhang²,

Yan³

et al. 2021

DMSO

View full text Add to dashboard Cite

show abstract

“…We close this chapter by reporting the results of a meta-analysis carried out by Pala E et al [57]. The inclusion criteria established for the selection of studies considered only articles (n = 16) that evaluated c-miR levels in PM woF OP vs. PM woF CTRs.…”

Section: Pm Op Vs Prm Ctrsmentioning

confidence: 99%

Circulating MicroRNAs as Novel Biomarkers for Osteoporosis and Fragility Fracture Risk: Is There a Use in Assessment Risk?

Ciuffi

Donati

Marini

et al. 2020

IJMS

View full text Add to dashboard Cite

Osteoporosis is a multifactorial skeletal disease that is associated with both bone mass decline and microstructure damage. The fragility fractures—especially those affecting the femur—that embody the clinical manifestation of this pathology continue to be a great medical and socioeconomic challenge worldwide. The currently available diagnostic tools, such as dual energy X-ray absorptiometry, Fracture Risk Assessment Tool (FRAX) score, and bone turnover markers, show limited specificity and sensitivity; therefore, the identification of alternative approaches is necessary. As a result of their advantageous features, such as non-invasiveness, biofluid stability, and easy detection, circulating cell-free miRs are promising new potential biomarkers for the diagnosis of osteoporosis and low-traumatic fracture risk assessment. However, due to the absence of both standardized pre-analytical, analytical, and post-analytical protocols for their measurement and universally accepted guidelines for diagnostic use, their clinical utility is limited. The aim of this review was to record all the data currently available in the literature concerning the use of circulating microRNAs as both potential biomarkers for osteoporosis diagnosis and fragility fracture risk evaluation, and group them according to the experimental designs, in order to support a more conscious choice of miRs for future research in this field.

show abstract

“…Mandourah et al (2018) validated the up-regulation of miR-122-5p and miR-4516 in OP patients by RT-qPCR based on five subgroups of human blood sample control studies, i.e., non-OP controls, osteopenia without fracture, osteopenia with fracture, OP without fracture, OP without fracture. In another mate-analysis, samples collected from 327 PMO patients and 328 post-menopausal health samples were analyzed, and robust rank aggregation (RRA) was used to determine the up-regulation of miR-133a-3p in the blood of OP patients (Pala and Denkceken, 2019). Ma et al 2019verified that miR-181c-5p and miR-497-3p were down regulated in the blood of 86 post-menopausal women with OP or osteopenia, and increased after treatment with bisphosphonate and calcitriol, suggesting the role of diagnosis and treatment of OP.…”

Section: Overview Of the Collected Mirnasmentioning

confidence: 99%

MicroRNA Alterations for Diagnosis, Prognosis, and Treatment of Osteoporosis: A Comprehensive Review and Computational Functional Survey

Zhang

et al. 2020

Front. Genet.

View full text Add to dashboard Cite

Osteoporosis (OP) is a systemic bone disease with a series of clinical symptoms. The use of screening biomarkers in OP management is therefore of clinical significance, especially in the era of precision medicine and intelligent healthcare. MicroRNAs (miRNAs) are small, non-coding RNAs with the potential to regulate gene expression at the post-transcriptional level. Accumulating evidence indicates that miRNAs may serve as biomarkers for OP prediction and prevention. However, few studies have emphasized the role of miRNAs in systems-level pathogenesis during OP development. In this article, literature-reported OP miRNAs were manually collected and analyzed based on a systems biology paradigm. Functional enrichment studies were performed to decode the underlying mechanisms of miRNAs in OP etiology and therapeutics in three-dimensional space, i.e., integrated miRNA-gene-pathway analysis. In particular, interactions between miRNAs and three well-known OP pathways, i.e., estrogenendocrine, WNT/β-catenin signaling, and RANKL/RANK/OPG, were systematically investigated, and the effects of non-genetic factors on personalized OP prevention and therapy were discussed. This article is a comprehensive review of OP miRNAs, and bridges the gap between an understanding of OP pathogenesis and clinical translation.

show abstract

Differentially expressed circulating miRNAs in postmenopausal osteoporosis: a meta-analysis

Cited by 26 publications

References 57 publications

Overexpression of miR125b Promotes Osteoporosis Through miR-125b-TRAF6 Pathway in Postmenopausal Ovariectomized Rats

Overexpression of miR125b Promotes Osteoporosis Through miR-125b-TRAF6 Pathway in Postmenopausal Ovariectomized Rats

Circulating MicroRNAs as Novel Biomarkers for Osteoporosis and Fragility Fracture Risk: Is There a Use in Assessment Risk?

MicroRNA Alterations for Diagnosis, Prognosis, and Treatment of Osteoporosis: A Comprehensive Review and Computational Functional Survey

Contact Info

Product

Resources

About